List of Teflaro drug patents

Teflaro is owned by Allergan.

Teflaro contains Ceftaroline Fosamil.

Teflaro has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Teflaro are:

  • US6417175

Teflaro was authorised for market use on 29 October, 2010.

Teflaro is available in powder;intravenous dosage forms.

Teflaro can be used as methods for treating bacterial infections, method of treating bacterial infections.

The generics of Teflaro are possible to be released after 10 February, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6417175 ALLERGAN Phosphonocephem derivatives, process for the preparation of the same, and use thereof
Apr, 2022

(9 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629861 ALLERGAN Compositions and methods for treating bacterial infections using ceftaroline
Sep, 2030

(7 years from now)

US8247400 ALLERGAN Cephem compounds useful for the treatment of bacterial infections
Feb, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Sep 13, 2022

Drugs and Companies using CEFTAROLINE FOSAMIL ingredient

Market Authorisation Date: 29 October, 2010

Treatment: Method of treating bacterial infections; Methods for treating bacterial infections

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of TEFLARO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in